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Abstract
Background:  Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and
cholesterol levels through their action as peroxisome proliferator-activated receptor alpha
(PPARα) agonists. The activation of PPARα leads to a cascade of events that result in the
pharmacological (hypolipidemic) and adverse (carcinogenic) effects in rodent liver.
Results: To understand the molecular mechanisms responsible for the pleiotropic effects of
PPARα agonists, we treated mouse primary hepatocytes with three PPARα agonists (bezafibrate,
fenofibrate, and WY-14,643) at multiple concentrations (0, 10, 30, and 100 μM) for 24 hours. When
primary hepatocytes were exposed to these agents, transactivation of PPARα was elevated as
measured by luciferase assay. Global gene expression profiles in response to PPARα agonists were
obtained by microarray analysis. Among differentially expressed genes (DEGs), there were 4, 8, and
21 genes commonly regulated by bezafibrate, fenofibrate, and WY-14,643 treatments across 3
doses, respectively, in a dose-dependent manner. Treatments with 100 μM of bezafibrate,
fenofibrate, and WY-14,643 resulted in 151, 149, and 145 genes altered, respectively. Among them,
121 genes were commonly regulated by at least two drugs. Many genes are involved in fatty acid
metabolism including oxidative reaction. Some of the gene changes were associated with
production of reactive oxygen species, cell proliferation of peroxisomes, and hepatic disorders. In
addition, 11 genes related to the development of liver cancer were observed.
Conclusion: Our results suggest that treatment of PPARα agonists results in the production of
oxidative stress and increased peroxisome proliferation, thus providing a better understanding of
mechanisms underlying PPARα agonist-induced hepatic disorders and hepatocarcinomas.
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Background
Peroxisome proliferators are structurally diverse chemi-
cals that include industrial pollutants, plasticizers, herbi-
cides, and lipid-lowering drugs. Fibrates including
bezafibrate, clofibrate, fenofibrate, WY-14,643, and oth-
ers are a unique class of hypolipidemic drugs. They func-
tion as agonists for peroxisome proliferator-activated
receptor alpha (PPARα). PPARα is a transcriptional
nuclear receptor and forms a heterodimer with another
nuclear receptor, retinoid X receptor (RXR). PPARα/RXR
heterodimer binds effectively to the peroxisome prolifera-
tor response elements (PPREs) located in promoters of
various target genes and regulate the expression of genes
involved in lipid metabolism and peroxisome prolifera-
tion [1-3]. PPRE consists of direct repeats of TGA/TCCT
which is separated by a single nucleotide (DR1) [4].
Fibrates reduce plasma triglyceride and cholesterol levels
via the activation of PPARα, which is considered to be the
result of induction of fatty acid catabolism in the liver. At
the molecular level, fibrates bind to PPARα and increase
the expression of genes that involved in fatty acid uptake
(fatty acid binding protein, FABP), β-oxidation (acyl-CoA
oxidase, ACOX), and ω-oxidation (cytochrome P450) [4-
7]. This pharmacological effect of fibrates is responsible
for the therapeutic utility, and this effect was observed in
preclinical species and also in humans.
Along with the pharmacological effects of fibrates, toxic
effects such as marked peroxisome proliferation,
hepatomegaly and hepatocarcinoma are observed in
rodents [8]. It is accepted that the mode of action (hepa-
tocarcinogenesis) is dependent upon sustained PPARα
activation. This mode of action is supported by the obser-
vation that even a one year exposure to PPARα agonists
was insufficient to cause an increase in the incidence of
hepatic neoplasms in PPARα knock-out mice. In addition,
peroxisome proliferation and gene expression regulated
by PPARα were not remarkably altered. One hypothesis
for the carcinogenic mechanism of action of PPARα ago-
nists in rodent liver is based on their ability to elevate per-
oxisomal  β-oxidation and microsomal ω-oxidation of
fatty acids, resulting in the generation of hydrogen perox-
ide. This excess production of hydrogen peroxide results
in the generation of reactive oxygen species (ROS) and
oxidative stress [9]. The induction of oxidative stress has
been suggested as a common pathway for many non-gen-
otoxic carcinogens to elicit their carcinogenicity [10]. In
addition, increased peroxisome proliferation in response
to activation by PPARα agonists is associated with tumor
formation in rodent liver [8]. The combined effect of
increased oxidative stress and increased cell proliferation
in the rodents exposed to PPARα agonists likely underlies
their carcinogenic potential. The precise mechanism of
the hepatocarcinogenesis of PPARα agonists in rodents is
not fully understood. Since a number of fibrates (e.g., bez-
afibrate and fenofibrate) are used as therapeutic agents, it
is important to analyze the mechanism of liver toxic
effects occurred in rodents so that we can better evaluate
the safety of these drugs.
Microarray technology provides a comprehensive, rapid
and efficient method for large scale profiling of gene
expression changes in biological samples (e.g., treatment
versus control, disease versus normal). The advantages of
DNA microarray technology include the ability to analyze
expression patterns of thousands of genes simultaneously.
Other advantages include the ability to characterize rela-
tionships between genes and the changes in biological
processes such as disease states, developmental stages and
responses to drugs [10,11]. This method has been success-
fully employed in identifying gene expression changes in
cells, including both hepatic cell lines [12] and isolated
hepatocytes [13], in response to various stimuli.
In this study, using mouse primary hepatocytes, we exam-
ined global gene expression profiles observed after treat-
ment with several concentrations of three PPARα agonists
(i.e. bezafibrate, fenofibrate and WY-14,643). The gene
expression profiles showed increased expression of genes
involved in fatty acid oxidation and metabolism as
expected, and also showed regulation of many genes
involved in the production of ROS and those that are
associated with liver cancer development. This study also
demonstrates the similarity of gene expression changes
induced by three different PPARα agonists. In addition,
this whole genome microarray analysis performed follow-
ing in vitro administration of PPARα agonists indicates a
plausible mechanism of hepatocarcinogenesis in the
mouse liver and may help with the safety assessment of
this class of agents.
Results
PPARα agonist administration to primary hepatocytes to 
assess PPARα activity
In order to estimate whether PPARα activity was elevated
by the addition of PPARα agonists, pHD(x3) luciferase
plasmid containing three direct tandem copies of a PPRE
binding site was used as a reporter plasmid. Primary hepa-
tocytes were co-transfected with pHD(x3) luc reporter
plasmid and pSG5-PPARα or pSG5-PPARα/pSG5-RXR
expression vectors. Twenty-four hours after transfection,
cells were treated with PPARα agonist at various concen-
trations (10–100 μM) for 24 h. Basal level of luciferase
activity was observed (data not shown) when cells were
transfected with pHD(x3) luc reporter plasmid and pGS5
empty vector. This could be due to the activity of endog-
enous PPARα agonists (i.e., fatty acid and their metabo-
lites) [5,14]. Figure 1 shows that mouse primary
hepatocytes transfected with pHD(x3) luc reporter plas-
mid and pGS5 empty vector produced 1.2, 0.8, and 1.8BMC Bioinformatics 2006, 7(Suppl 2):S18
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fold increased in luciferase activity after the treatment
with 100 μM bezafibrate, fenofibrate, and WY-14,643,
respectively. When cells were treated with the same con-
centration of drugs in the presence of PPARα expression
plasmid, the induction of luciferase activities increased to
2.3, 3.4 and 5.0 fold. Moreover, in the presence of both
PPARα and RXR expression plasmids, luciferase activities
increased even further to 6.6, 7.1, and 9.9 fold. PPARα
activation inductions by these three agonists demonstrate
a does-dependent increase for 100 μM compare wtih 10
and 30 μM treatments (Figure 1).
Gene expression patterns associated with exposures of 
PPARα agonists
To understand the molecular mechanisms responsible for
the pleiotropic effects of fibrates, mouse primary hepato-
cytes were treated with three PPARα agonists (Figure 1).
RNA was isolated following 24 h treatment and the Agi-
lent Whole Mouse Genome Microarray analysis was per-
formed. Three replicate arrays corresponding to each
treatment (10, 30 and 100 μM) of each drug (bezafibrate,
fenofibrate and WY-14,643) were compared to the con-
trol replicates (DMSO) using Student t-test. A gene was
considered to be significantly regulated by a drug if the
fold change was greater than 1.5 and the P-value was less
than 0.05. Based on these two criteria, there were 4, 26,
and 151 genes that showed an altered expression by the
treatments with 10, 30 and 100 μM bezafibrate, respec-
tively. There were 9, 41 and 149 genes altered by 10, 30
and 100 μM fenofibrate, and 31, 52 and 145 genes altered
by the treatment with 10, 30 and 100 μM WY-14,643. The
Venn diagrams (Figure 2) represent the numbers of differ-
entially expressed genes (DEGs) from three drug treat-
ments at various concentrations. Among these DEGs, 4, 8,
and 21 genes were altered in common by bezafibrate,
fenofibrate and WY-14,643 treatments across 3 doses,
respectively (Figure 2). These commonly regulated genes
showed clear dose-dependent changes (Figure 3). Except
for the down regulation of Ahsg by WY-14,643, all genes
were identified as up-regulated. Expression of Pdk4 and
Cte1 showed a particularly prominent induction (10–20
fold at 100 μM) by treatment of WY-14,643 (Fig. 3C), as
did Fabp1 with 20–30 fold induction by 100 μM treat-
ments of fenofibrate and WY-14,643 (Figs. 3B &3C).
Hierarchical clustering analysis with DEGs revealed that
these genes were grouped together based on treatment
doses rather than on specific drugs (Figure 4), indicating
that a class effect was detectable. Taking into considera-
tion the fact that most of the genes altered by low (10 μM)
and middle (30 μM) dose treatments were also altered by
high (100 μM) dose treatments, further analysis was
focused on the genes regulated by the high dose treat-
ments. Figure 5 represents the numbers of genes regulated
by the 100 μM treatments of three drugs and the numbers
of overlapping genes among three drug treatments. Treat-
ments with 100 μM of bezafibrate, fenofibrate and WY-
14,643 resulted in 151, 149 and 145 genes with altered
expression, respectively. Among them, 61 genes were con-
cordantly regulated by three drugs and 121 genes were
regulated commonly by at least 2 drugs. The correlation of
log2 fold changes based on 61 genes which were regulated
commonly by three drugs was determined by pairwise
comparisons (Table 1). Comparison of gene expression
profiles resulted in relatively high correlations (0.94–
0.97) between three drug treatments, indicating that gene
expression patterns are identical at the 100 μM concentra-
tion despite any differences among the drugs.
Gene function analysis
Using Ingenuity Pathway Analysis, we conducted gene
function analysis with these 121 commonly regulated
genes. Not surprisingly, the largest categories of induced
genes were those involved in lipid metabolism (49 genes),
including oxidation, modification, and metabolism.
Table 2 shows the genes involved in oxidation (19 genes),
of which 10 were involved in β-oxidation. As expected,
many genes directly regulated by PPARα including Cpt1
(carnitine palmitoyltransferase 1), Fabp1 (fatty acid bind-
ing protein 1), Acox1 (acyl-Coenzyme A oxidase 1, palmi-
toyl), and Ehhadh (enoyl-Coenzyme A, hydratase/3-
Activation of PPARα by three PPARα agonists Figure 1
Activation of PPARα by three PPARα agonists. Pri-
mary hepatocytes were co-transfected with a luciferase 
reporter construct containing PPRE and with or without 
PPARα/RXR expression vectors. Twelve hours after trans-
fection, three PPARα agonists, bezafibrate, fenofibrate and 
WY-14,643 were added at the concentrations as indicated. 
Cells were harvested after 24 h drug treatment. Luciferase 
activity was normalized against β-galactosidase activity. The 
groups having three bars indicate different treatments with 
the concentrations of 10, 30 and 100 μM, from left to right. 
Error bars represent standard derivations of two replicates.
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hydroxyacyl Coenzyme A dehydrogenase) were identified
in this study. Induction of these genes corroborates previ-
ous data, and also serves as the validation of our micro-
array experiments. Several novel genes including Acacb,
Acsl1, Ech1, Hadhb, and Pdk4 that are involved in oxida-
tion of lipid metabolism were responsive to the treat-
ments of PPARα agonists. In addition, four genes
(Aldh3a2, Apoc2, Cd36, and Slc25a10) associated with
the production of ROS exhibited 1.5–3.0 fold up-regula-
tion, and two genes (Acox1 and Pex11a) involved in the
cellular proliferation of peroxisomes were 3-fold up-regu-
lated.
Administration of fibrates to rodents results in hepatic
diseases and hepatocarcinoma [8]. For gene function
analysis, we also concentrated on genes involved in these
effects. There were six genes related to hepatic disorders
(Table 3), and all were up-regulated by fibrate administra-
tion. Four of these genes are involved in oxidation of lip-
ids. In addition, 11 genes classified as being related to the
Numbers of genes regulated by drug treatments Figure 2
Numbers of genes regulated by drug treatments. Numbers of significant genes (FC > 1.5, P < 0.05) regulated by bezafi-
brate, fenofibrate and WY-14,643 at the various concentrations of 10, 30 and 100 μM. Numbers of genes commonly regulated 
at low, middle and high dose are presented in Venn diagram.
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development of liver cancer had altered expression levels.
These include liver fatty acid binding protein 1 (Fabp1),
lymphocyte antigen 6 complex locus D (Ly6d),
monoglyceride lipase (Mgll), and angiopoietin-like 4
(Angptl4), with a wide range of up-regulation (1.6–34.4
fold) after treatments with these three PPARα agonists.
Discussion
Fibrates, members of peroxisome proliferators and ago-
nists of PPARα, are used to treat hyperlipidemia by reduc-
ing plasma triglyceride and cholesterol levels via
accelerating lipid metabolism. In rodents, administration
of fibrates can induce hepatomegaly and hepatocarci-
noma, possibly due to the induction of cell proliferation
and increased oxidative stress. Examination of PPARα-
deficient mice demonstrated that the activation of PPARα
is required exclusively for mediating both pharmacologi-
cal (hypolipidemic) and toxic (carcinogenic) responses of
fibrate administration [15,16]. However, mechanisms of
fibrate-induced hepatocarcinoma development and the
potential risk of use of these drugs to humans remain
unclear. Examination of gene expression profiles is an
important approach that may help us better understand
PPARα-mediated pleiotropic effects.
In this study, microarray analysis was applied to generate
a molecular portrait of gene expression in mouse primary
hepatocytes exposed to fibrates (Figure 1). We treated
mouse primary hepatocytes with three fibrates (bezafi-
brate, fenofibrate and WY-14,643) at multiple doses (0,
10, 30, and 100 μM). Although global gene analysis study
was conducted in vitro [17], the design of this study (i.e.,
Dose-dependency of gene expression Figure 3
Dose-dependency of gene expression. Genes commonly regulated at low, middle and high dose levels were selected.
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Two-dimensional hierarchical cluster analysis (HCA) of significant genes induced by bezafibrate, fenofibrate and WY-14,643 Figure 4
Two-dimensional hierarchical cluster analysis (HCA) of significant genes induced by bezafibrate, fenofibrate and WY-14,643.BMC Bioinformatics 2006, 7(Suppl 2):S18
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treatment with multiple fibrates at multiple level doses)
permitted us to detect whether changes in gene expres-
sions are a class effect (e.g., genes are commonly regulated
by multiple drugs) and whether changes are dose-depend-
ent as well. Indeed, the majority of genes regulated by low
and middle doses were also identified in high dose treat-
ments. For example, 4/4, 9/9, and 25/31 genes that were
regulated by 10 μM treatments of bezafibrate, fenofibrate
and WY-14,643, respectively, were also found to be regu-
lated in 100 μM treatments (Figure 2). In addition, dose-
response dependency in gene expressions was also
observed for the genes commonly regulated at multiple
doses (Figure 3). The dose-dependent expression levels of
genes altered by PPARα agonists allowed us to assess bio-
logical activity of this class of agents.
PPARα agonists have a therapeutic role in the manage-
ment of fatty acid metabolism through their effects on β-
oxidation and lipid transport. The gene expression
changes in common across PPARα agonists may indicate
those genes are directly regulated by PPARα stimulation.
In this study, we demonstrated that 121 DEGs were
altered in common by at least two of the three PPARα ago-
nists tested. The Ingenuity Pathway Analysis was used to
analyze gene functions and to provide pathway annota-
tions. Based on this analysis, many of these genes (49
genes) are involved in the oxidation of fatty acids (Table
2) as has been previously shown for this class of agents
[4,18]. For example, acyl-coA synthetase catalyzes the pre-
cursor step to β-oxidation (ligates CoA to a free fatty acid)
and three members of the long chain acyl CoA synthestase
family (Acsl1, Acsl4, and Acsl5) were increased. This
observation is supported by the work of Schoonjans et al.
who demonstrated that the expression of Acs is altered by
fibrates and that there is a PPRE in the Acsl promoter [19].
These findings also agree with those of Cornwall et al.
who reported that the expression of Acsl was elevated in
the liver of rats exposed to fenofibrate [20]. The effects on
the β-oxidation pathway also include the induction of the
first enzyme of peroxisomal β-oxidation, acyl-CoA oxi-
dase (Acox), as well as the next enzyme in the cascade,
enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase
(Ehhadh). The identification of a large number of lipid
metabolizing genes following exposure to several PPARα
agonists is in concordance with the known biochemical
and molecular effects of these hypolipidemic agents to
regulate lipid metabolism.
PPARα agonists are also considered to be nongenotoxic
carcinogens in rodents. Oxidative stress has been pro-
posed as a common pathway for many non-genotoxic car-
cinogens [21]. In the present study, 10 genes involved in
fatty acid β-oxidation were up-regulated upon exposure to
PPARα agonists (Table 2), which included Acox, the key
enzyme of peroxisomal fatty acid β-oxidation system. The
elevation of peroxisomal fatty acid β-oxidation such as
occurs with PPARα agonist exposure in rodents results in
the elevated generation of hydrogen peroxide [9]. Sub-
stantial production of hydrogen peroxide causes oxidative
stress and the induction of ROS. The increased ROS asso-
ciated with elevated levels of Acox has been postulated to
mediate the hepatocarcinogenesis resulting from PPARα
exposure in rodents. We observed four genes (Aldh3a2,
Apoc2, Cd36, and Slc25a10) associated with the produc-
tion of ROS were up-regulated. A growing body of evi-
dence indicates that Cd36 (CD36 antigen) is involved in
Table 1: Correlation coefficients of Log2 FC for 100 μM treatments with different PPARα agonists
Bezafibrate Fenofibrate WY-14,643
Bezafibrate 1.0000 0.9652 0.9642
Fenofibrate 0.9652 1.0000 0.9419
WY-14,643 0.9642 0.9419 1.0000
Distribution and overlap of significant genes (fc > 1.5 and p <  0.05) among bezafibrate fenofibrate and WY-14,643 treat- ments of 100 μM Figure 5
Distribution and overlap of significant genes (fc > 1.5 and p < 
0.05) among bezafibrate fenofibrate and WY-14,643 treat-
ments of 100 μM.
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the cytotoxicity associated with inflammation and is an
essential mediator of the production of ROS [22]. In addi-
tion, six genes classified as related to hepatic disorders
were identified as being up-regulated (Table 3). These
observations support the hypothesis that increased perox-
isome proliferation results in oxidative stress, which may
be due to the disproportionate increase in the level of oxi-
dation versus antioxidation enzyme activities [8].
It is believed that the activation of PPARα and ensuing
cascade effects are linked to both pharmacological and
tumorigenic effects of PPARα agnoists [8]. The carcino-
genic response seems likely to be associated with both the
induction of oxidative stress and the increased cell prolif-
eration from peroxisome proliferation after treatment
with these chemicals. In this study, we found that two
genes (Acox1 and Pex11a) associated with cellular prolif-
eration of peroxisomes were up-regulated about 3-fold.
The level of peroxisomal biogenesis factor 11 (Pex11) cor-
relates roughly with peroxisome abundance in the cell,
and over-expression of Pex11 alone is sufficient to acceler-
ate peroxisome division and to increase peroxisome abun-
dance [23]. It is thought that alteration in the balance
between cell proliferation and apoptosis is causally
related to the induction of liver tumors, and induced cell
proliferation plays a key role in carcinogenesis in animals
and humans [24,25].
Based on the Ingenuity Pathway Analysis, 11 genes associ-
ated with liver cancer development were up-regulated by
at least two PPARα agonists tested (Table 3). For example,
Bnip3 (BCL2 19 kDa-interacting protein 1), a pro-apop-
totic factors of the Bcl-2-family, has been previously
shown to be up-regulated in malignant tumors [26].
Diazepam binding inhibitor (Dbi), interacts with hepato-
cyte nuclear factor-4 α that transcriptionally regulates the
genes involved in both lipid and glucose metabolism
[27], was also increased. Previous studies indicated that
Dbi levels are higher in hepatocellular carcinoma (HCC)
patients [28], and the elevation of Dbi expression is useful
in evaluating malignancy and in diagnostic approaches of
tumors in liver tissue [29]. Fatty acid-binding proteins
(Fabps) are involved in lipid metabolism by intracellular
transport of long-chain fatty acids. Liver fatty acid-binding
protein (Fabp1) is demonstrated immunohistochemically
in human hepatocellular malignancies, suggesting that its
immunoreactivity is a candidate for the tumor marker in
hepatic cell malignancies [30]. Fatty acid synthase (Fasn)
is the key enzyme of de novo fatty acid synthesis. The over-
expression of Fasn is an early phenomenon presented in
Table 2: Genes involved in oxidation in mouse primary hepatocytes treated with 100 μM of 3 drugs for 24 hours
Gene symbol Gene description Locus link ID Bezafibrate Fenofibrate WY-14,643
fc p fc p fc p
*Abcd3 ATP-binding cassette, sub-family D (ALD), member 3 19299 1.88 0.032 1.97 0.017
Acacb acetyl-Coenzyme A carboxylase beta 100705 2.99 0.000 2.85 0.009 3.26 0.008
*Acadvl acyl-Coenzyme A dehydrogenase, very long chain 11370 1.97 0.000 2.11 0.017
*Acox1 acyl-Coenzyme A oxidase 1, palmitoyl 11430 2.91 0.019 3.01 0.012
Acsl1 acyl-CoA synthetase long-chain family member 1 14081 1.92 0.033 2.04 0.013 2.40 0.001
Acsl4 acyl-CoA synthetase long-chain family member 4 50790 1.75 0.005 1.91 0.012 1.66 0.019
Acsl5 acyl-CoA synthetase long-chain family member 5 433256 1.67 0.010 1.57 0.018 1.55 0.001
Aldh1a2 aldehyde dehydrogenase family 1, subfamily A2 19378 2.13 0.013 2.12 0.043
Cd36 CD36 antigen 12491 3.00 0.017 2.93 0.032
*Cpt1a carnitine palmitoyltransferase 1a, liver 12894 1.52 0.000 1.61 0.015
*Ech1 enoyl coenzyme A hydratase 1, peroxisomal 51798 2.79 0.011 2.64 0.007 2.57 0.005
*Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase
74147 7.12 0.000 7.38 0.001 7.61 0.004
Fabp1 fatty acid binding protein 1, liver 14080 27.80 0.001 34.35 0.004 20.96 0.014
*Hadha hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit
97212 1.95 0.035 1.81 0.002 1.92 0.000
*Hadhb hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit
231086 2.24 0.020 2.18 0.004 2.24 0.007
*Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 15488 1.53 0.023 1.67 0.012
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 27273 10.18 0.012 8.68 0.004 19.88 0.000
Scd stearoyl-Coenzyme A desaturase 1 20249 5.50 0.004 4.51 0.023
*Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 26458 2.79 0.019 2.98 0.026
*Ten genes also involved in β-oxidation. fc, Fold change; p, P-value.BMC Bioinformatics 2006, 7(Suppl 2):S18
Page 9 of 12
(page number not for citation purposes)
both hormonally and chemically induced rat hepatocar-
cinogenesis [31]. Hypoxia inducible factor-1 alpha
(Hif1a) regulates the expression of a myriad of genes
involved in oxygen transport, glucose uptake, glycolysis
and angiogenesis. The expression of Hif1a in HCC tissue
is higher than that in paraneoplastic tissue or normal liver
tissue, and Hif1a plays an important role in neovasculari-
zation in HCC [32]. Lgals3 (lectin) has been demon-
strated to be associated with assorted processes such as
cell growth, tumor transformation and metastasis. It has
been reported that Lgals3 expression was induced in cir-
rhotic liver and HCC, and that the expression of Lgals3 in
proliferating cells possibly indicates an early neoplastic
event [33]. The plasminogen activation system, including
PAI-1 (plasminogen activator inhibitor 1), plays a crucial
role in the process of cancer. PAI-1 is increased in HCC,
and its expression is related to the invasiveness, metasta-
sis, and prognosis [34,35]. Our findings support the
observation that PPARα agonists increase proliferation of
peroxisomes in rodent hepatocytes and alter lipid metab-
olism. In addition, the gene expression profiles indicate a
number of leads toward understanding PPARα agonist-
induced hepatocarcinogenesis in the mouse.
Conclusion
In summary, primary mouse hepatocytes were treated
with various concentrations (10, 30, 100 μM) of three
PPARα agonists (bezafibrate, fenofibrate, and WY-
14,643) for 24 hr. Transactivation analysis indicated that
these three agents activated the PPARα in a dose-depend-
ent manner. Global gene expression analysis was per-
formed on whole mouse genome arrays following
exposure of the mouse hepatocyte cultures to PPARα ago-
nists. Hierarchal clustering analysis of these gene expres-
sion profiles indicated that expression profiles of DEGs
were clustered based on doses rather than specific drugs,
indicating there is a common effect across this class of
compound. Gene expression changes were detected in
mouse hepatocytes following exposure to 100 μM bezafi-
brate (151 genes), fenofibrate (149 genes), and WY-
14,643 (145 genes). The expression of 121 genes was
changed in common by at least two of the PPARα agonists
tested. Based on Ingenuity Pathway Analysis, many of
these genes (49) function in lipid metabolism. An addi-
tional 11 genes were mapped to cancer associated func-
tions. Clear dose-dependent changes in DEGs were
determined based on magnitude of fold change. These
results provide a better understanding of the underlying
mechanisms of the hepatic effects of PPARα agonists in
the mouse.
Materials and methods
Chemicals and cell treatments
Bezafibrate and fenofibrate were purchased from Sigma
(St. Louis, MO). WY-14,643 was purchased from Chem-
syn Science Laboratories (Lenexa, KS). All compounds
Table 3: Genes associated with hepatic diseases and liver cancer development in mouse primary hepatocytes treated with 100 μM of 3 
drugs for 24 hours (based on Ingenuity Pathway Analysis)
Gene symbol Gene description Locus link ID Beza Feno WY
fc p fc p fc p
Hepatic diseases
Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 18670 1.72 0.006 2.06 0.029
Acox1 acyl-Coenzyme A oxidase 1, palmitoyl 11430 2.91 0.019 3.01 0.012
Fabp1 fatty acid binding protein 1, liver 14080 27.80 0.001 34.35 0.004 20.96 0.014
Hadha hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit
97212 1.95 0.035 1.81 0.002 1.92 0.000
Insig1 insulin induced gene 1 231070 1.68 0.001 1.64 0.000
Scd stearoyl-Coenzyme A desaturase 1 20249 5.50 0.004 4.51 0.023
Liver cancer development
Angptl4 angiopoietin-like 4 57875 2.24 0.009 1.87 0.017 2.28 0.011
Bnip3 BCL2 19kDa-interacting protein 1 12176 1.97 0.014 2.31 0.036
Dbi diazepam binding inhibitor 13167 1.88 0.006 1.82 0.005 1.68 0.035
Fabp1 fatty acid binding protein 1, liver 14080 27.80 0.001 34.35 0.004 20.96 0.014
Fabp2 fatty acid binding protein 2, intestinal 14079 2.88 0.020 2.91 0.014
Fasn fatty acid synthase 14104 2.03 0.014 1.89 0.015 1.72 0.000
Hif1a hypoxia inducible factor 1, alpha subunit 15251 1.70 0.012 1.64 0.033
Lgals3 lectin, galactose binding, soluble 3 16854 1.89 0.023 2.05 0.000
Ly6d lymphocyte antigen 6 complex, locus D 17068 5.21 0.012 4.23 0.000 5.56 0.000
Mgll monoglyceride lipase 23945 3.51 0.028 3.78 0.013 3.34 0.008
Serpine1 serine peptidase inhibitor, clade E, mem1 18787 2.35 0.016 2.52 0.013
(fc, Fold change; p, P-value; Beza, bezafibrate; Feno, fenofibrate; WY, WY-14,643)BMC Bioinformatics 2006, 7(Suppl 2):S18
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were prepared as 1000 x stock solutions in dimethyl sul-
foxide (DMSO) and added to cell cultures in final concen-
trations of 10–100 μM. The same amount of DMSO
(0.1% v/v) was added to control cells. During the treat-
ments, serum-free medium was used with supplements
(see below).
Three 6–8 week-old C57/BL6 male mice were obtained
from the breeding colony of the FDA's National Center for
Toxicological Research. Mice were anesthetized with 1.5
ml/kg of nembutal sodium solution containing 50 mg/ml
of pentobarbital sodium prior to undergoing liver per-
fusion. All animals used in this study were handled in
accordance with the principles and guidelines prepared by
the National Institutes of Health, USA. Mouse primary
hepatocytes were isolated by a two-stage collagenase per-
fusion process according to the methods described by Seg-
len et al. and Kreamer et al. [36,37]. Primary hepatocytes
were suspended in L-15 medium containing 2 mg/ml
BSA, 18 mM HEPES, 3 mg/ml proline, 1 mg/ml galactose,
0.1% insulin-transferrin-selenite, 10 ng/ml epidermal
growth factor, 50 U/ml penicillin, and 50 μg/ml strepto-
mycin. The cells were treated with drugs six hours after
plating.
Plasmid transfection and reporter assays
Luciferase reporter plasmid, pHD(x3) luc, contains three
direct tandem copies of PPRE binding site, was used as
previously described [38]. pSG5-PPARα and pSG5-RXR
expression plasmids were obtained from Dr. Marek
Michalak (University of Alberta, Canada). Plasmid DNAs
were purified by column chromatography (Qiagen Inc.,
Valencia, CA). Primary hepatocytes were plated in L15
medium at 1 × 105 cells/per well for 6 wells, and transfec-
tions were carried out after cell attachment with FuGENE
reagent (Roche Diagnostics, Indianapolis, IN). Briefly,
300 μl of L15 (no additives) containing 9 μl of FuGENE
reagent was mixed with a total of 3 μg of plasmid DNA
with or without pSG5-PPARα/pSG5-RXR, luciferase
reporter plasmid, and pSVβ-gal (internal control). This
mixture was added to cells for a 10 min incubation at
room temperature. For induction, medium was replaced
with fresh L15 without BSA after 12 h incubation with
plasmids/FuGENE. The PPARα agonists were added for
24 h at appropriate concentrations. To harvest lysates for
luciferase activity, hepatocytes were washed twice in PBS,
and then lysed in 150 μl of 1x reporter lysis buffer
(Promega Corp., Madison, WI). Luciferase activity was
measured using the Luciferase Assay System (Promega).
Luminescence was determined using an automatic lumi-
nometer, LumiTeum II (Harta Instruments, Gaithersburg,
MD). β-galactosidase enzyme assay was carried out using
β-galactosidase Enzyme Assay System (Promega). Luci-
ferase activity was normalized against β-galactosidase
activity from the same lysate. Each assay was performed in
duplicates.
RNA isolation and quality control
Total RNA from cells was isolated using an RNeasy system
(Qiagen). The yield of the extracted RNA was determined
spectrophotometrically by measuring the optical density
at 260 nm. The purity and quality of extracted RNA were
evaluated using the RNA 6000 LabChip and Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Only high quality RNA with RNA integrity numbers
(RINs) greater than 7.5 were used for microarray experi-
ments.
Preparation of labeled in vitro transcribed cRNA targets
All total RNA samples were labeled by direct incorpora-
tion of cyanine 3 or cyanine 5 dyes using the Agilent Low
RNA Input Linear Amplification Kit (Santa Clara, CA). A
500 ng quantity of total RNA was input to each reaction.
Labeled cRNAs were purified using the Qiagen RNeasy
Mini kit, and were analyzed for quality and quantity using
standard UV spectrometry and the Agilent Bioanalyzer.
Hybridization of labeled cRNA to microarrays and 
microarray imaging
Cyanine 3 labeled cRNAs were mixed with cyanine 5
labeled cRNAs for hybridization to microarrays. Each test
sample was hybridized against its corresponding control
sample to two microarrays in a dye-swapped pair. Agilent
Whole Mouse Genome Microarrays (Santa Clara, CA)
were hybridized using the Agilent Gene Expression
Hybridization kit and washed using Agilent Gene Expres-
sion Wash Buffers according to the manufacturers' proto-
cols. Hybridized microarrays were scanned using the
Agilent DNA Microarray Scanner and data were extracted
from images using the Agilent Feature Extraction (version
7.5) software using default settings.
Microarray data analysis
The Agilent Whole Mouse Genome Microarray that con-
tains 43,790 probes was used to generate gene expression
profiles for bezafibrate, fenofibrate, and WY-14,643 at
three dose levels (10 μM, 30 μM and 100 μM) with three
biological replicates (hepatocytes isolated from mouse A,
B, C). Each treated sample was paired with a control (non-
treated hepatocytes) using a dye swap experiment design,
resulting in 54 arrays [3 chemicals × 3 doses × 3 animals
× (2 dye swap)]. In addition, self-self hybridizations were
also conducted for each of three controls with three tech-
nical replicates, resulting in nine additional arrays. In
total, 63 hybridizations were performed for this study.
Linear & Lowess method consists of median scaling to
1000 for each channel per array with a follow up Lowess
normalization. The parameters used in Lowess normaliza-BMC Bioinformatics 2006, 7(Suppl 2):S18
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tion were: smoothing factor = 0.2 and robustness itera-
tions = 3. Low intensity (<500) spots were filtered out
after normalization and a subset of 25,010 genes was gen-
erated for further data analysis. The DEGs were identified
using a combination of Student t-test and fold change
(FC). A gene was considered differentially expressed if P-
value was less than 0.05 and the FC was greater than 1.5.
Two lists of DEGs were obtained. One list was obtained by
comparing the nine self-self hybridization arrays with
those polarity+ arrays in which control and treatment
samples were labeled with Cy3 and Cy5, respectively. The
other list was obtained by comparing the nine self-self
hybridization arrays with those polarity- arrays in which
control and treatment samples were labeled with Cy5 and
Cy3, respectively. The genes in common between these
two lists of DEGs were considered as final DEGs and used
for biological interpretation. The described analysis
approach, in terms of self-self hybridization experiment
design, will be reported somewhere else, where its com-
parative performance analysis was conducted.
Microarray data management and analysis were con-
ducted using an FDA microarray software, ArrayTrack
[39,40]. ArrayTrack also provides functionality for the
interpretation of gene expression data. For example, path-
way analysis is based on the Pathway Library in
ArrayTrack, which contains pathways from Kyoto Ency-
clopedia of Genes and Genomes (KEGG) [41] and PathArt
(Jubilant Biosys Ltd., Columbia, MD). The Fisher Exact
Test [42] is implemented in ArrayTrack to assess the statis-
tical significance of identified pathways. Ingenuity Path-
way Analysis software (Mountain View, CA) was also used
for gene function and pathway analysis. S-Plus (Insightful
Corp., Seattle, WA) was used in this study for the statistical
calculation.
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